Actos Bladder Cancer Lawsuits Continue, New Complaint Filed by Tennessee Resident

Actos Bladder Cancer Lawsuits Continue, New Complaint Filed by Tennessee ResidentActos bladder cancer lawsuitscontinue, with a new complaint filed by a resident of Tennessee. The national law firm, Parker Waichman LLP, represents the Tennessee man who alleges that Actos caused his bladder cancer.

The lawsuit was filed on June 14th in the U.S. District Court for the Western District of Louisiana (Case No. 6:12-cv-1663). The case is pending in the multidistrict litigation as part of In Re: Actos (Pioglitazone) Products Liability Litigation and Jerrold S. Parker, founding partner of Parker Waichman, has been appointed to the Plaintiff’s Steering Committee. The defendants in this case are Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceutical Company Limited, and Eli Lilly and Co.

The complaint states the man took Actos from approximately 2002 – 2011 and alleges that Actos caused the man to develop bladder cancer in December 2004. The lawsuit also alleges that Actos caused severe mental and physical pain and suffering, past and future permanent injuries and emotional distress, economic loss due to medical expenses, and living related expenses caused by his new lifestyle; the lawsuit seeks compensation on behalf of the patient’s wife for loss of consortium.

According to the lawsuit, the man could have avoided the effects and injuries he suffered had the defendants properly informed the public of the risks. The lawsuit also alleges that the makers of Actos knew, or should have known, about the risks associated with Actos, specifically, the significant increased risk of bladder cancer following a year of use, and that, because the defendants failed to warn the public of these risks, patients have been unnecessarily exposed to bladder cancer.

The U.S. Food and Drug Administration (FDA) approved Actos as a Type 2 diabetes drug in 1999. The agency notified the public about the drug’s link to bladder cancer in a September 2010 Safety Announcement; according to preliminary results of an ongoing ten-year study, an increased risk was associated with using Actos for at least two years. Last June, the FDA updated this information, warning that the link is apparent after just one year of exposure. According to the information in this second Safety Announcement, users were 40 percent likelier to develop bladder cancer after just one year of use, versus people who had never taken Actos. The agency also pointed out that the risk for bladder cancer increased with time and dosage.

Around the same time, Actos use was suspended in France and Germany following a French Medicines Agency-funded study revealing an increased risk, after one year of use, in male diabetic patients taking Actos. A recent study published in the British Medical Journal (BMJ) supported the Actos-bladder cancer risk and revealed that two years of exposure to Actos correlated with a two-fold increased risk for diabetes.

Parker Waichman LLP, recently filed another lawsuit on behalf of another man who developed bladder cancer after taking Actos in which the same defendants were named. That complaint alleges that the plaintiff developed bladder cancer in July 2009 after he had taken Actos from 2007 to 2011 and that Actos caused the bladder cancer and other subsequent adverse events due to his long-term, prescribed use of the drug. Just prior, Parker Waichman LLP also filed a lawsuit on behalf of the estate of a Kentucky man who developed bladder cancer and subsequently died, allegedly due to his prescribed use of Actos between 2010 and 2011, says the complaint, which alleges that taking Actos caused him to develop bladder cancer, from which he died last November.

We also just wrote that a newly published study is raising concerns that patients who take Actos or Avandia may face an increased risk of developing diabetic macular edema, an eye disorder that can result in vision loss. The study found that type 2 diabetics who use thiazolidinediones, a group of drugs that includes Actos and Avandia, had a two-to-three times greater higher risk of macular edema. The risk was higher if patients used insulin in combination with the drugs.

Some legal experts believe that Takeda Pharmaceuticals, the maker of Actos, could eventually be named in as many as 10,000 Actos side effect lawsuits.

This entry was posted in Actos, Pharmaceuticals and tagged . Bookmark the permalink.

© 2005-2019 Parker Waichman LLP ®. All Rights Reserved.